@article{4626,
  keywords = {Humans, Influenza, Human, Microfluidics, COVID-19, SARS-CoV-2},
  author = {Nicole Welch and Meilin Zhu and Catherine Hua and Juliane Weller and Marzieh Mirhashemi and Tien Nguyen and Sreekar Mantena and Matthew Bauer and Bennett Shaw and Cheri Ackerman and Sri Thakku and Megan Tse and Jared Kehe and Marie-Martine Uwera and Jacqueline Eversley and Derek Bielwaski and Graham McGrath and Joseph Braidt and Jeremy Johnson and Felecia Cerrato and Gage Moreno and Lydia Krasilnikova and Brittany Petros and Gabrielle Gionet and Ewa King and Richard Huard and Samantha Jalbert and Michael Cleary and Nicholas Fitzgerald and Stacey Gabriel and Glen Gallagher and Sandra Smole and Lawrence Madoff and Catherine Brown and Matthew Keller and Malania Wilson and Marie Kirby and John Barnes and Daniel Park and Katherine Siddle and Christian Happi and Deborah Hung and Michael Springer and Bronwyn MacInnis and Jacob Lemieux and Eric Rosenberg and John Branda and Paul Blainey and Pardis Sabeti and Cameron Myhrvold},
  title = {Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants.},
  abstract = { <p>The coronavirus disease 2019 (COVID-19) pandemic has demonstrated a clear need for high-throughput, multiplexed and sensitive assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses and their emerging variants. Here, we present a cost-effective virus and variant detection platform, called microfluidic Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (mCARMEN), which combines CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical use. We developed the mCARMEN respiratory virus panel to test for up to 21 viruses, including SARS-CoV-2, other coronaviruses and both influenza strains, and demonstrated its diagnostic-grade performance on 525 patient specimens in an academic setting and 166 specimens in a clinical setting. We further developed an mCARMEN panel to enable the identification of 6 SARS-CoV-2 variant lineages, including Delta and Omicron, and evaluated it on 2,088 patient specimens with near-perfect concordance to sequencing-based variant classification. Lastly, we implemented a combined Cas13 and Cas12 approach that enables quantitative measurement of SARS-CoV-2 and influenza A viral copies in samples. The mCARMEN platform enables high-throughput surveillance of multiple viruses and variants simultaneously, enabling rapid detection of SARS-CoV-2 variants.</p> },
  year = {2022},
  journal = {Nat Med},
  volume = {28},
  pages = {1083-1094},
  month = {2022 May},
  issn = {1546-170X},
  doi = {10.1038/s41591-022-01734-1},
  language = {eng},
}